Product Comparison


  Seqirus USA Inc 70461041910 Seqirus USA Inc 70461031903 Seqirus USA Inc 33332041910 Seqirus USA Inc 33332021920
McKesson # 1121575 1121577 1121562 1121569
Description Flucelvax® Quadrivalent 2019 - 2020 Flu Vaccine 60 mcg / 0.5 mL Indicated For People 4 Years of Age and Above Multiple Dose Vial 5 mL Flucelvax® Quadrivalent 2019 - 2020 Flu Vaccine 60 mcg / 0.5 mL Indicated For People 4 Years of Age and Above Prefilled Syringe 0.5 mL Afluria® Quadrivalent 2019 - 2020 Flu Vaccine 60 mcg / 0.5 mL Indicated for People 6 Months of Age and Above Multiple Dose Vial 5 mL Afluria® Quadrivalent 2019 - 2020 Pediatric Flu Vaccine 30 mcg / 0.25 mL Indicated For People 6 Months to 35 Months of Age Prefilled Syringe 0.25 mL
Manufacturer # 70461041910704610319033333204191033332021920
Brand Flucelvax® Quadrivalent 2019 - 2020Flucelvax® Quadrivalent 2019 - 2020Afluria® Quadrivalent 2019 - 2020Afluria® Quadrivalent 2019 - 2020 Pediatric
Manufacturer Seqirus USA IncSeqirus USA IncSeqirus USA IncSeqirus USA Inc
Invoice FLUCELVAX 2019, QUAD MDV 5ML (10DOSE/VL)FLUCELVAX 2019, QUAD SYR 0.5ML(10DOSE/BX)AFLURIA 2019, QUAD MDV 5ML (10DOSE/VL)AFLURIA 2019, QUAD SYR 0.25ML PED (10DOSE/BX)
    Log In to Order   Log In to Order   Log In to Order   Log In to Order

Comparison

Container Type Multiple Dose VialPrefilled SyringeMultiple Dose VialPrefilled Syringe
Country of Origin United StatesUnited StatesAustraliaAustralia
NDC Number 70461041910704610319033333204191033332021920
Strength 60 mcg / 0.5 mL60 mcg / 0.5 mL60 mcg / 0.5 mL30 mcg / 0.25 mL
User Indicated For People 4 Years of Age and AboveIndicated For People 4 Years of Age and AboveIndicated For People 6 Months of Age and AboveIndicated For People 6 Months to 35 Months of Age
Volume 5 mL0.5 mL5 mL0.25 mL
Application Flu VaccineFlu VaccineFlu VaccineFlu Vaccine
Dosage Form InjectionInjectionInjectionInjection
Storage Requirements Requires RefrigerationRequires RefrigerationRequires RefrigerationRequires Refrigeration
Type IntramuscularIntramuscularIntramuscularIntramuscular
UNSPSC Code 51201608512016085120160851201608
Features and Benefits
  • FLUCELVAX QUADRIVALENT is an inactivated vaccine indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine
  • FLUCELVAX is approved for use in persons 4 years of age and older
  • FLUCELVAX QUADRIVALENT 5 mL multi-dose vial formulation contains no antibiotics
  • FLUCELVAX QUADRIVALENT is standardized according to United States Public Health Service requirements for the 2019-2020 influenza season and is formulated to contain a total of 60 micrograms (mcg) hemagglutinin (HA) per 0.5 mL dose in the recommended ratio of 15 mcg HA of each of the following four influenza strains:
  • A/Idaho/07/2018 (an A/Brisbane/02/2018 (H1N1)pdm09-like virus), A/Indiana/08/2018 (an A/Kansas/14/2017 (H3N2)-like virus), B/Iowa/06/2017 (a B/Colorado/06/2017-like virus), B/Singapore/INFTT-16-0610/2016 (a B/Phuket/3073/2013-like virus)
  • FLUCELVAX QUADRIVALENT is an inactivated vaccine indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine
  • FLUCELVAX is approved for use in persons 4 years of age and older
  • FLUCELVAX QUADRIVALENT 0.5 mL pre-filled syringes contain no preservative or antibiotics
  • FLUCELVAX QUADRIVALENT is standardized according to United States Public Health Service requirements for the 2019-2020 influenza season and is formulated to contain a total of 60 micrograms (mcg) hemagglutinin (HA) per 0.5 mL dose in the recommended ratio of 15 mcg HA of each of the following four influenza strains:
  • A/Idaho/07/2018 (an A/Brisbane/02/2018 (H1N1)pdm09-like virus), A/Indiana/08/2018 (an A/Kansas/14/2017 (H3N2)-like virus), B/Iowa/06/2017 (a B/Colorado/06/2017-like virus), B/Singapore/INFTT-16-0610/2016 (a B/Phuket/3073/2013-like virus)
  • AFLURIA QUADRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine
  • AFLURIA QUADRIVALENT is approved for use in persons 6 Months and older
  • The multi-dose presentation contains thimerosal added as a preservative; each 0.5 mL dose contains 24.5 mcg of mercury
  • AFLURIA QUADRIVALENT is standardized according to USPHS requirements for the 2019-2020 influenza season and is formulated to contain 60 mcg hemagglutinin (HA) per 0.5 mL dose in the recommended ratio of 15 mcg HA for each of the four influenza strains recommended for the 2019-2020 Northern Hemisphere influenza season:
  • A/Brisbane/02/2018 (IVR-190) (an A/Brisbane/02/2018 (H1N1)pdm09 – like virus), A/Kansas/14/2017 (X-327) (an A/Kansas/14/2017 (H3N2) – like virus), B/Maryland/15/2016 (a B/Colorado/06/2017 – like virus) and B/Phuket/3073/2013 BVR-1B (a B/Phuket/3073/2013 – like virus). A 0.25 mL dose contains 7.5 mcg HA of each of the same four influenza strains.
  • AFLURIA® QUADRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine.
  • 5 mL multi-dose vial ( for persons 6 months of age and older).
  • AFLURIA QUADRIVALENT is a sterile suspension for intramuscular injection
  • AFLURIA QUADRIVALENT is standardized according to USPHS requirements for the 2019-2020 influenza season and is formulated to contain 60 mcg hemagglutinin (HA) per 0.5 mL dose in the recommended ratio of 15 mcg HA for each of the four influenza strains recommended for the 2019-2020 Northern Hemisphere influenza season:
  • A/Brisbane/02/2018 (IVR-190) (an A/Brisbane/02/2018 (H1N1)pdm09 – like virus), A/Kansas/14/2017 (X-327) (an A/Kansas/14/2017 (H3N2) – like virus), B/Maryland/15/2016 (a B/Colorado/06/2017 – like virus) and B/Phuket/3073/2013 BVR-1B (a B/Phuket/3073/2013 – like virus). A 0.25 mL dose contains 7.5 mcg HA of each of the same four influenza strains.